Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AZN Shareholders Have Opportunity to Lead AstraZeneca PLC Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
07:00am, Thursday, 09'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PL
3 Cheap Growth Stocks to Buy in 2025
06:45am, Thursday, 09'th Jan 2025
As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the content
Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
05:45am, Thursday, 09'th Jan 2025
NEW YORK , Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class peri
Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact Levi & Korsinsky
11:00pm, Wednesday, 08'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, fol
NEW ORLEANS, Jan. 08, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 21, 2025 to file lead plaintiff applications in a se
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, fol
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ:AZN) between February 23, 2022 and Dec
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
07:20pm, Wednesday, 08'th Jan 2025
The latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close.
Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact Levi & Korsinsky
07:15pm, Wednesday, 08'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, fol
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, fol
AstraZeneca (AZN) Reels from China Investigation and Investor Suit - Hagens Berman
12:45pm, Wednesday, 08'th Jan 2025
AZN Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / AstraZeneca (NASDAQ:AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price t
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.
Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
12:30pm, Wednesday, 08'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, fol
AstraZeneca PLC Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
12:30pm, Wednesday, 08'th Jan 2025
LOS ANGELES, CA / ACCESSWIRE / January 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca"
NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised t
